gene therapy

| PR Fire

Applied Biopharm Consulting partners with South East Technological University to advance viral vector research

CORK, REPUBLIC OF IRELAND. May 20th, 2026 – Applied Biopharm Consulting Ltd has announced a new research collaboration with the Pharmaceutical and Molecular Biotechnology Research Centre (PMBRC) at the South East Technological University (SETU) in Waterford, Ireland, to experimentally validate aspects of its artificial intelligence (AI)-driven biomolecular research programme. The collaboration is supported through the […]

Applied Biopharm Consulting partners with South East Technological University to advance viral vector research Read More »

ioosjy82b6woa4to0uxm44lvfptd | PR Fire

Lentitek secures £250k seed investment to commercialize enabling biotechnologies for advanced cancer treatments and gene therapies

  Edinburgh, UK – 30 May 2023 – Edinburgh based Lentitek Ltd (Lentitek), a developer of pioneering manufacturing technologies enabling economic delivery of advanced cell and gene therapies, announced today that it has secured £250,000 ($300,000 USD) in seed investment.  This investment will be deployed to further advance its technology and commence initial commercial trials. 

Lentitek secures £250k seed investment to commercialize enabling biotechnologies for advanced cancer treatments and gene therapies Read More »

ioosjy82b6woa4to0uxm44lvfptd | PR Fire

Lentitek secures £250k seed investment to commercialize enabling biotechnologies for advanced cancer treatments and gene therapies

  Edinburgh, UK – 30 May 2023 – Edinburgh based Lentitek Ltd (Lentitek), a developer of pioneering manufacturing technologies enabling economic delivery of advanced cell and gene therapies, announced today that it has secured £250,000 ($300,000 USD) in seed investment.  This investment will be deployed to further advance its technology and commence initial commercial trials. 

Lentitek secures £250k seed investment to commercialize enabling biotechnologies for advanced cancer treatments and gene therapies Read More »

ioosjy82b6woa4to0uxm44lvfptd | PR Fire

Lentitek secures £250k seed investment to commercialize enabling biotechnologies for advanced cancer treatments and gene therapies

  Edinburgh, UK – 30 May 2023 – Edinburgh based Lentitek Ltd (Lentitek), a developer of pioneering manufacturing technologies enabling economic delivery of advanced cell and gene therapies, announced today that it has secured £250,000 ($300,000 USD) in seed investment.  This investment will be deployed to further advance its technology and commence initial commercial trials. 

Lentitek secures £250k seed investment to commercialize enabling biotechnologies for advanced cancer treatments and gene therapies Read More »